iBio Inc. (IBIO), and GE Healthcare, the healthcare business of GE (GE), announced a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines. The alliance builds on the existing development and marketing deal between the two companies announced in 2010 and combines iBio's innovative plant-based vaccine manufacturing platform, iBioLaunch, with GE Healthcare's capabilities in start-to-finish technologies for biopharmaceutical manufacturing. Financial terms were not disclosed.
iBio's research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology would continue to play a key role in advancing the iBioLaunch platform.
GE Healthcare's global team of bioengineers and bioprocessing scientists are working with researchers from iBio and CMB to develop a single, flexible facility which could significantly reduce the capital and operating costs of biotherapeutic and vaccine manufacture compared with traditional animal cell and microbial based methods.
For comments and feedback: editorial@rttnews.com